Ostarine 10mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Usage

1. Establish your baseline.: Before beginning, note your fasted bodyweight, dietary caloric target, and training schedule — recomposition results are only measurable against a documented starting point.
2. Take one 10mg tablet daily with water.: Ostarine's 24-hour half-life supports once-daily dosing; consistency of timing (e.g. morning with breakfast) is more important than the specific hour.
3. Do not split tablets.: Each tablet is compressed and coated as a single 10mg unit; splitting introduces dosing error. If you require 20mg, take two whole tablets simultaneously.
4. Maintain a high-protein diet throughout.: MK-2866 supports protein synthesis signalling, but dietary protein (1.6–2.2g per kg bodyweight, per ISSN guidelines) is the substrate those pathways require — the compound does not substitute for nutritional adequacy.
5. Track performance markers weekly.: Strength output on compound lifts and tape measurements are the most practical early indicators of recomposition progress; rely on these rather than scale weight alone, which fluctuates with water balance.
6. Plan your off-cycle before you start.: A standard beginner cycle (6–8 weeks at 10mg) is followed by a minimum 4-week break; have your post-cycle support protocol — including a SERM if bloodwork or symptom assessment warrants it — confirmed before day one of the cycle.

Warnings

Frequently asked questions

Why is Ostarine MK-2866 widely considered the safest SARM for beginners?

Ostarine is considered the most beginner-appropriate SARM because its androgen receptor selectivity produces measurable anabolic effects at doses (10–20mg/day) where testosterone suppression remains mild and reversible in most users. Its 24-hour half-life supports once-daily dosing without peaks, and the extensive phase I/II clinical dataset from GTx Inc. gives it the most documented human safety profile of any SARM currently researched.

Can Ostarine MK-2866 preserve lean muscle mass during a calorie deficit?

Yes — muscle preservation during a caloric deficit is one of the primary evidence-supported use cases for MK-2866. By selectively activating androgen receptors in skeletal muscle, Ostarine maintains protein synthesis signalling even when total caloric intake is reduced, countering the catabolic environment that normally degrades lean tissue during a cut. This is why it is consistently recommended in recomposition protocols rather than pure bulk cycles.

What is the standard beginner Ostarine dosage and cycle length?

The standard beginner protocol for Ostarine is 10mg per day for 6–8 weeks. Clinical research (GTx Phase II, 2011) demonstrated statistically significant lean mass changes at doses as low as 3mg, confirming that 10mg is biologically active and does not require higher doses for a first cycle. Advanced users may increase to 20–25mg, but beginners should complete at least one full cycle at 10mg before adjusting upward.

What is the advantage of a 10mg tablet for dosing Ostarine compared to higher-strength tabs?

The 10mg unit dose is the most precise starting format available for MK-2866. Users can progress from 10mg to 20mg daily by adding one whole tablet, avoiding the inaccuracy introduced when splitting higher-dose tablets. For a first SARM cycle — where the goal is to establish individual response at the lowest effective dose — this granular control over daily intake is a meaningful practical advantage over 25mg or 30mg formats.

How many tablets are in one pack and is it sufficient for a full beginner cycle?

Each Elbrus Pharmaceuticals Ostarine pack contains 60 tablets at 10mg per tablet. At the standard beginner dose of 10mg daily, a single pack covers a complete 60-day (approximately 8-week) cycle without requiring a second order. At 20mg daily, the 60-tablet pack supports a 4-week cycle — making it versatile for both conservative first-time protocols and slightly higher intermediate doses. (2) angle_used

Manufacturer

Elbrus Pharmaceuticals' approach to its MK-2866 tablet line can be understood through a single operational principle the brand has held since its founding: the credibility gap in the research-compound market is not a chemistry problem — it is a documentation problem. Potent, technically pure APIs have been widely available from bulk chemical suppliers for years; what has been consistently absent is batch-level analytical evidence that the declared API actually reached the finished tablet at the declared concentration. For Ostarine, Elbrus closes that gap through a two-stage verification architecture. The first stage is raw material intake assessment: incoming MK-2866 API is identity-confirmed and purity-checked against specification before it enters the tablet compression queue — sub-specification material is rejected at this point, not adjusted for in downstream processing. The second stage is finished-tablet HPLC potency verification, performed on the compressed and coated tablet itself rather than extrapolated from the API certificate. Both results, alongside LAL endotoxin clearance data, are assigned to the specific batch lot number before any unit is released for distribution. This structure reflects the founding design logic of the Elbrus quality framework: that a research compound's integrity must be demonstrable at the point of use, not assumed from the point of manufacture.